November 11, 2019   AMD risk phenotypes targeted in direct-to-consumer genetic database Genetic testing can identify patients with high-risk genotypes for age-related macular degeneration, says Theodore Leng, MD, MS. Learn more ADVERTISEMENT   Focusing the battle against dry AMD Andreas F. Borkenstein, MD, discusses a unique device in the fight against dry age-related macular degeneration. Find out ADVERTISEMENT   Anti-VEGFs pose no additional risk of SAEs over other therapies Anti-VEGF therapy does not increase the risk of systemic serious adverse events in DME patients compared with patients treated with macular laser photocoagulation or intravitreal corticosteroid, according to a recent real-world analysis of patients in a large U.S. insurance database. Learn more ADVERTISEMENT   ADVERTISEMENT Be curious. Be excited. Be informed. Novartis is pleased to announce that BEOVU® (brolucizumab-dbll) injection has been approved by the Food and Drug Administration (FDA) and is now available. Learn more. © 2019 Novartis 10/19 BVU-138129797   RELATED ARTICLES Connecting the dots: Genetics and impact on diabetic retinopathy Laser therapy maintains position as key DME treatment option US, international physicians mostly in agreement over treatment practices Retina risk app tool empowers diabetic patients worldwide